Cloud Hosting

Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009;15:76576.

Article CAS PubMed Central PubMed Google Scholar

Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47:82033.

Article CAS PubMed Central PubMed Google Scholar

Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, et al. Tissue determinants of human NK cell development, function, and residence. Cell. 2020;180:749763.e13.

Article CAS PubMed Central PubMed Google Scholar

Buckle I, Johnson A, Rojas IL, Weinert V, Sester DP, Radford K, et al. High dimensional analysis reveals distinct NK cell subsets but conserved response to stimulation in umbilical cord blood and adult peripheral blood. Eur J Immunol. 2023;53:2250118.

Article CAS Google Scholar

Wang W. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6. https://doi.org/10.3389/fimmu.2015.00368.

Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:6528.

CAS PubMed Google Scholar

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM, Greiner JW, et al. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016;7:8635973.

Article PubMed Central PubMed Google Scholar

Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15:156370.

Article CAS PubMed Google Scholar

Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:7.

Article CAS PubMed Central PubMed Google Scholar

Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107:15966.

Article CAS PubMed Central PubMed Google Scholar

Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, et al. Ex Vivoexpanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015;38:2436.

Article CAS PubMed Central PubMed Google Scholar

Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, et al. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. 2022;139:117783.

Article CAS PubMed Central PubMed Google Scholar

Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123:385563.

Article CAS PubMed Central PubMed Google Scholar

Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:30517.

Article CAS PubMed Google Scholar

Heuser M, Tschan-Plessl A, Thol F, Schwarzer A, Kloos A, Kattre N, et al. Allogeneic, CD34 +, umbilical cordblood-derived NK cell adoptive immunotherapy for the treatment of acute myeloid leukemia patients with measurable residual disease. Blood. 2021;138:17451745.

Article Google Scholar

Choi I, Yoon SR, Park S-Y, Kim H, Jung S-J, Kang Y-L, et al. Donor-derived natural killer cell infusion after human leukocyte antigenhaploidentical hematopoietic cell transplantation in patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2016;22:206576.

Article CAS PubMed Google Scholar

Bachanova V, Maakaron JE, Cichocki F, McKenna DH, Cao Q, DeFor TE, et al. Gda-201, a novel metabolically enhanced allogeneic natural killer (NK) cell product yields high remission rates in patients with relapsed/refractory non-Hodgkin lymphoma (NHL): 2-year survival and correlation with cytokine IL7. Blood. 2021;138:38543854.

Article Google Scholar

Nangia C, Soon-Shiong P, Rabizadeh S, Lee JH, Sender L, Jones F, et al. Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK). Ann Oncol. 2019;30:v130.

Article Google Scholar

Fate Therapeutics. Fate therapeutics announces encouraging dose-escalation clinical data of FATE-NK100 and provides regulatory update on landmark IND appli cation for FT500 [Press Release]. 2018. https://ir.fatetherapeutics.com/press-releases?field_nir_news_date_value%5Bmin%5D.

Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:18599.

Article CAS PubMed Google Scholar

Yoon DH, Koh Y, Park H, Hwang YK, Kim WS. A phase 1 study of the combination of MG4101, ex vivo -expanded allogeneic NK cells and rituximab for relapsed or refractory Non-Hodgkin Lymphoma. Blood. 2020;136:1415.

Article Google Scholar

Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, et al. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother. 2018;67:48394.

Article CAS PubMed Google Scholar

Liang S, Lin M, Niu L, Xu K, Wang X, Liang Y, et al. Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC). Am J Cancer Res. 2018;8:87991.

CAS PubMed Central PubMed Google Scholar

Lin M, Luo H, Liang S, Chen J, Liu A, Niu L, et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest. 2020;130:25609.

Article CAS PubMed Central PubMed Google Scholar

Chung YY, Park SW, Im J-M, Yoo D-K, Cheon H-C, Kim J-E, et al. Abstract CT171: combinatorial allogeneic NK cell therapy with Pembrolizumab for cholangiocarcinoma; interim report of open label Phase1/2a study. Cancer Res. 2021;81:CT171CT171.

Article Google Scholar

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, et al. In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: a phase I clinical trial. OncoImmunology. 2018;7:e1424673.

Article CAS PubMed Central PubMed Google Scholar

Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, et al. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. Clin Cancer Res. 2017;23:64419.

Article CAS PubMed Central PubMed Google Scholar

Talleur AC, Triplett BM, Federico S, Mamcarz E, Janssen W, Wu J, et al. Consolidation therapy for newly diagnosed pediatric patients with high-risk neuroblastoma using Busulfan/Melphalan, autologous hematopoietic cell transplantation, anti-GD2 antibody, granulocyte-macrophage colonystimulating factor, interleukin-2, and haploidentical natural killer cells. Biol Blood Marrow Transplant. 2017;23:19107.

Article CAS PubMed Central PubMed Google Scholar

Schmidt P, Raftery MJ, Pecher G. Engineering NK cells for CAR therapyrecent advances in gene transfer methodology. Front Immunol. 2021;11:611163.

Article PubMed Central PubMed Google Scholar

Gong Y, Klein Wolterink RGJ, Janssen I, Groot AJ, Bos GMJ, Germeraad WTV. Rosuvastatin enhances VSV-G lentiviral transduction of NK cells via upregulation of the low-density lipoprotein receptor. Mol Ther Methods Clin Dev. 2020;17:63446.

Article CAS PubMed Central PubMed Google Scholar

Mller S, Bexte T, Gebel V, Kalensee F, Stolzenberg E, Hartmann J, et al. High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia. Front Immunol. 2020;10:3123.

Article PubMed Central PubMed Google Scholar

Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. Overview of approved CART therapies, ongoing clinical trials, and its impact on clinical practice. eJHaem. 2022;3:610.

Article PubMed Google Scholar

Zhang X, Guo Y, Ji Y, Gao Y, Zhang M, Liu Y, et al. Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report. Cell Transpl. 2022;31:096368972210942.

Article Google Scholar

Klingemann H. Are natural killer cells superior CAR drivers? OncoImmunology. 2014;3:e28147.

Article PubMed Central PubMed Google Scholar

Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:10839.

CAS PubMed Central PubMed Google Scholar

Fate Therapeutics. Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Of-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed/Refrac tory B-cell Lymphoma at 2021 ASH Annual Meeting [Press Release]. 2021. https://ir.fatetherapeutics.com/press-releases?field_nir_news_date_value%5Bmin%5D=2021.

Bachanova V, Cayci Z, Lewis D, Maakaron JE, Janakiram M, Bartz A, et al. Initial clinical activity of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma. Blood. 2020;136:88.

Article Google Scholar

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:54553.

Article CAS PubMed Central PubMed Google Scholar

Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024. https://doi.org/10.1038/s41591-023-02785-8.

Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8:297310.

Article CAS PubMed Google Scholar

Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, et al. CD 19 CAR engineered NK 92 cells are sufficient to overcome NK cell resistance in Bcell malignancies. J Cell Mol Med. 2016;20:128794.

Article CAS PubMed Central PubMed Google Scholar

Oelsner S, Waldmann A, Billmeier A, Rder J, Lindner A, Ullrich E, et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3positive BALL and inhibit in vivo leukemia growth. Int J Cancer. 2019;145:193545.

Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28:91727.

Article CAS PubMed Google Scholar

Mansour AG, Teng K-Y, Li Z, Zhu Z, Chen H, Tian L, et al. Off-the-shelf CARengineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 2023;7:622539.

Article CAS PubMed Central PubMed Google Scholar

Chen Y, You F, Jiang L, Li J, Zhu X, Bao Y, et al. Gene-modified NK-92MI cells expressing a chimeric CD16-BB- or CD64-BB- receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody. Oncotarget. 2017;8:3712839.

Article PubMed Central PubMed Google Scholar

Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, et al. Targeting CD20+ aggressive B-cell NonHodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res. 2015;3:33344.

Article CAS PubMed Google Scholar

Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15:163.

Article CAS PubMed Central PubMed Google Scholar

Klaihmon P, Kang X, Issaragrisil S, Luanpitpong S. Generation and functional characterization of anti-CD19 chimeric antigen receptor-natural killer cells from human induced pluripotent stem cells. IJMS. 2023;24:10508.

Article CAS PubMed Central PubMed Google Scholar

Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. 2020;136:230818.

Article PubMed Central PubMed Google Scholar

Albinger N, Bexte T, Buchinger L, Wendel P, Al-Ajami A, Gessner A, et al. CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML. Blood. 2022;140:45589.

Article Google Scholar

Portillo AL, Hogg R, Poznanski SM, Rojas EA, Cashell NJ, Hammill JA, et al. Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. iScience. 2021;24:102619.

Article ADS CAS PubMed Central PubMed Google Scholar

Ao X, Yang Y, Li W, Tan Y, Guo W, Ao L, et al. Anti-FR CAR-engineered NK-92 cells display potent cytotoxicity against FR-positive ovarian cancer. J Immunother. 2019;42:28496.

Article CAS PubMed Central PubMed Google Scholar

Liu WN, So WY, Harden SL, Fong SY, Wong MXY, Tan WWS, et al. Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model. Sci Adv. 2022;8:eadd1187.

More:

Development of NK cell-based cancer immunotherapies through receptor engineering | Cellular & Molecular Immunology - Nature.com